Euroopa Liit -
eesti -
EMA (European Medicines Agency)
inlyta
pfizer europe ma eeig - aksitiniib - kartsinoom, neerurakk - protein kinase inhibiitorid - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.
Euroopa Liit -
eesti -
EMA (European Medicines Agency)
inrebic
bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastilised ained - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.
Eesti -
eesti -
Ravimiamet
itraconazol actavis kõvakapsel
teva b.v. - itrakonasool - kõvakapsel - 100mg 28tk; 100mg 15tk; 100mg 30tk; 100mg 4tk; 100mg 18tk
Eesti -
eesti -
Ravimiamet
cladosol 100mg kõvakapsel
stada arzneimittel ag - itrakonasool - kõvakapsel - 100mg 4tk; 100mg 14tk; 100mg 50tk; 100mg 6tk; 100mg 15tk; 100mg 30tk; 100mg 18tk; 100mg 28tk; 100mg 8tk; 100mg 84tk
Eesti -
eesti -
Ravimiamet
suphrex kõvakapsel
lv system service sia - sunitiniib - kõvakapsel - 12,5mg 30tk
Eesti -
eesti -
Ravimiamet
suphrex kõvakapsel
lv system service sia - sunitiniib - kõvakapsel - 50mg 30tk; 50mg 28tk